Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
The candidate at the center of AbbVie’s $8.7 billion Cerevel acquisition has failed a pair of phase 2 trials, delivering a boost to rival BMS.
Nick Paul Taylor
Nov 11, 2024 10:06am
Teva brings biotech ethos to drug development, exec says
Oct 15, 2024 4:33pm
Neurocrine's bid to save schizophrenia prospect fails
Sep 13, 2024 7:30am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Neumora schizophrenia drug on FDA hold over rabbit convulsions
Apr 15, 2024 9:00am
BMS' schizophrenia drug shows long-term benefit with new data
Apr 6, 2024 1:15pm
